Multicentered Observational Prospective Cohort Study on the Treatment of Metastatic Colorectal Cancer and the Role of Evaluating K-Ras
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Metastatic Colorectal Cancer
- Sponsor
- National Cancer Institute, Naples
- Enrollment
- 500
- Locations
- 4
- Primary Endpoint
- Percentage of patients with K-Ras mutation
- Status
- Active, not recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
The purpose of this study is to describe the treatments received and outcomes of patients with metastatic colorectal cancer, what percentage of these patients have K-Ras mutation of the tumor, and to describe the costs of treatments. Information will also be collected regarding risk factors, variables among treatment centers and patients, and explorative analyses will be done to try to identify factors that impact prognosis and factors that predict tolerability and response to treatment.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Histologic diagnosis colorectal carcinoma
- •Metastatic disease
- •Signed informed consent
Exclusion Criteria
- •Prior treatment of metastatic colorectal cancer
- •Refusal or incapability of providing informed consent
Outcomes
Primary Outcomes
Percentage of patients with K-Ras mutation
Time Frame: 2 years
percentage of patients enrolled in a clinical trial
Time Frame: two years
percentage of patients who undergo K-Ras mutation study
Time Frame: 2 years